* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:IDHC vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a Buyback Yield % of 0.00 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Integrated Diagnostics Holdings and its competitors. Over the past decade, Integrated Diagnostics Holdings' Buyback Yield % has ranged from 2.91 to 2.91. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #999999 out of 91 companies in the Medical Diagnostics & Research industry.
Is Integrated Diagnostics Holdings' Buyback Yield % too high?
Integrated Diagnostics Holdings' current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 2.91 to a high of 2.91. Based on the distribution chart, Integrated Diagnostics Holdings ranks #999999 out of 91 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #999999 out of 91 companies for Buyback Yield %. This places Integrated Diagnostics Holdings in the lower half of its industry. Historically, Integrated Diagnostics Holdings' own Buyback Yield % has ranged from 2.91 to 2.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.60, compared to a current price of $0.51 — trading 15% below its estimated fair value. The current Buyback Yield % is 0.00. Integrated Diagnostics Holdings' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Buyback Yield % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.51 is trading 15% below its estimated GF Value™ of $0.60.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
Buyback Yield %: 0.00
GF Value™: $0.60 vs. price of $0.51 (15% below fair value)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
59GF Score
Get the complete analysis for LSE:IDHC
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
